CXCL1-Mediated Interaction of Cancer Cells with Tumor-Associated Macrophages and Cancer-Associated Fibroblasts Promotes Tumor Progression in Human Bladder Cancer

Neoplasia (United States)

Volumn 18, Issue 10, 2016, Pages 636-646

  Miyake, Makito ^a   Hori, Shunta ^a   Morizawa, Yosuke ^a   Tatsumi, Yoshihiro ^a   Nakai, Yasushi ^a   Anai, Satoshi ^a   Torimoto, Kazumasa ^a   Aoki, Katsuya ^a   Tanaka, Nobumichi ^a   Shimada, Keiji ^a   Konishi, Noboru ^a   Toritsuka, Michihiro ^a   Kishimoto, Toshifumi ^a   Rosser, Charles J ^b   Fujimoto, Kiyohide ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF HAWAII CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CXCL1 CHEMOKINE; GELATINASE A; LENTIVIRUS VECTOR; UVOMORULIN; CYTOKINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLADDER CANCER; BLADDER CANCER CELL LINE; CANCER ASSOCIATED FIBROBLAST; CANCER CELL; CANCER PROGNOSIS; CANCER TISSUE; CANCER TRANSPLANTATION; CELL ADHESION; CELL INTERACTION; CLONE; COCULTURE; CONTROLLED STUDY; DISEASE COURSE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; ANIMAL; BIOLOGICAL MODEL; CELL LINE; DISEASE MODEL; FIBROBLAST; GENE EXPRESSION; GENETICS; MACROPHAGE; METABOLISM; PATHOLOGY; TUMOR INVASION; URINARY BLADDER NEOPLASMS;

ANIMALS; CELL ADHESION; CELL LINE; CHEMOKINE CXCL1; CYTOKINES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FIBROBLASTS; GENE EXPRESSION; HUMANS; MACROPHAGES; MICE; MODELS, BIOLOGICAL; NEOPLASM INVASIVENESS; TUMOR MICROENVIRONMENT; URINARY BLADDER NEOPLASMS;

EID: 85011048630     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1016/j.neo.2016.08.002     Document Type: Article

References (42)

1. [1] Siegel, R, Ma, J, Zou, Z, Jemal, A, Cancer statistics, 2014. CA Cancer J Clin 64 (2014), 9–29.
2. [2] Miyake, M, Gotoh, D, Shimada, K, Tatsumi, Y, Nakai, Y, Anai, S, Torimoto, K, Aoki, K, Tanaka, N, Konishi, N, et al. Exploration of risk factors predicting outcomes for primary T1 high-grade bladder cancer and validation of the Spanish Urological Club for Oncological Treatment scoring model: Long-term follow-up experience at a single institute. Int J Urol 22 (2015), 541–547.
3. [3] Hanahan, D, Weinberg, RA, Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
4. [4] Stadler, M, Walter, S, Walzl, A, Kramer, N, Unger, C, Scherzer, M, Unterleuthner, D, Hengstschläger, M, Krupitza, G, Dolznig, H, Increased complexity in carcinomas: Analyzing and modeling the interaction of human cancer cells with their microenvironment. Semin Cancer Biol 35 (2015), 107–124.
5. [5] Miyake, M, Lawton, A, Goodison, S, Urquidi, V, Gomes-Giacoia, E, Zhang, G, Ross, S, Kim, J, Rosser, CJ, Chemokine (C-X-C) ligand 1 (CXCL1) protein expression is increased in aggressive bladder cancers. BMC Cancer, 13, 2013, 322.
6. [6] Miyake, M, Lawton, A, Goodison, S, Urquidi, V, Rosser, CJ, Chemokine (C-X-C motif) ligand 1 (CXCL1) protein expression is increased in high-grade prostate cancer. Pathol Res Pract 210 (2014), 74–78.
7. [7] Miyake, M, Goodison, S, Urquidi, V, Gomes Giacoia, E, Rosser, CJ, Expression of CXCL1 in human endothelial cells induces angiogenesis through the CXCR2 receptor and the ERK1/2 and EGF pathways. Lab Investig 93 (2013), 768–778.
8. [8] Mantovani, A, Sica, A, Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 22 (2010), 231–237.
9. [9] Komohara, Y, Jinushi, M, Takeya, M, Clinical significance of macrophage heterogeneity in human malignant tumors. Cancer Sci 105 (2014), 1–8.
10. [10] Hao, NB, Lü, MH, Fan, YH, Cao, YL, Zhang, ZR, Yang, SM, Macrophages in tumor microenvironments and the progression of tumors. Clin Dev Immunol, 2012, 948098.
11. [11] Komohara, Y, Hasita, H, Ohnishi, K, Fujiwara, Y, Suzu, S, Eto, M, Takeya, M, Macrophage infiltration and its prognostic relevance in clear cell renal cell carcinoma. Cancer Sci 102 (2011), 1424–1431.
12. [12] Sugimoto, M, Mitsunaga, S, Yoshikawa, K, Kato, Y, Gotohda, N, Takahashi, S, Konishi, M, Ikeda, M, Kojima, M, Ochiai, A, et al. Prognostic impact of M2 macrophages at neural invasion in patients with invasive ductal carcinoma of the pancreas. Eur J Cancer 50 (2014), 1900–1908.
13. [13] Wang, B, Liu, H, Dong, X, Wu, S, Zeng, H, Liu, Z, Wan, D, Dong, W, He, W, Chen, X, et al. High CD204+ tumor-infiltrating macrophage density predicts a poor prognosis in patients with urothelial cell carcinoma of the bladder. Oncotarget 6 (2015), 20204–20214.
14. [14] Shigeoka, M, Urakawa, N, Nakamura, T, Nishio, M, Watajima, T, Kuroda, D, Komori, T, Kakeji, Y, Semba, S, Yokozaki, H, Tumor associated macrophage expressing CD204 is associated with tumor aggressiveness of esophageal squamous cell carcinoma. Cancer Sci 104 (2013), 1112–1119.
15. [15] Xouri, G, Christian, S, Origin and function of tumor stroma fibroblasts. Semin Cell Dev Biol 21 (2010), 40–46.
16. [16] Xing, F, Saidou, J, Watabe, K, Cancer associated fibroblasts (CAFs) in tumor microenvironment. Front Biosci 15 (2010), 166–179.
17. [17] Mishra, P, Banerjee, D, Ben-Baruch, A, Chemokines at the crossroads of tumor-fibroblast interactions that promote malignancy. J Leukoc Biol 89 (2011), 31–39.
18. [18] Kharaishvili, G, Simkova, D, Bouchalova, K, Gachechiladze, M, Narsia, N, Bouchal, J, The role of cancer-associated fibroblasts, solid stress and other microenvironmental factors in tumor progression and therapy resistance. Cancer Cell Int, 14, 2014, 41.
19. [19] Paulsson, J, Micke, P, Prognostic relevance of cancer-associated fibroblasts in human cancer. Semin Cancer Biol 25 (2014), 61–68.
20. [20] Herrera, M, Herrera, A, Domínguez, G, Silva, J, García, V, García, JM, Gómez, I, Soldevilla, B, Muñoz, C, Provencio, M, et al. Cancer-associated fibroblast and M2 macrophage markers together predict outcome in colorectal cancer patients. Cancer Sci 104 (2013), 437–444.
21. [21] Tsujino, T, Seshimo, I, Yamamoto, H, Ngan, CY, Ezumi, K, Takemasa, I, Ikeda, M, Sekimoto, M, Matsuura, N, Monden, M, Stromal myofibroblasts predict disease recurrence for colorectal cancer. Clin Cancer Res 13 (2007), 2082–2090.
22. [22] Nakayama, H, Enzan, H, Miyazaki, E, Naruse, K, Kiyoku, H, Hiroi, M, The role of myofibroblasts at the tumor border of invasive colorectal adenocarcinomas. Jpn J Clin Oncol 28 (1998), 615–620.
23. [23] Miyake, M, Goodison, S, Lawton, A, Gomes-Giacoia, E, Rosser, CJ, Angiogenin promotes tumoral growth and angiogenesis by regulating matrix metallopeptidase-2 expression via the ERK1/2 pathway. Oncogene 34 (2015), 890–901.
24. [24] Nogawa, M, Yuasa, T, Kimura, S, Tanaka, M, Kuroda, J, Sato, K, Yokota, A, Segawa, H, Toda, Y, Kageyama, S, et al. Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer. J Clin Invest 115 (2005), 978–985.
25. [25] Heneberg, P, Paracrine tumor signaling induces transdifferentiation of surrounding fibroblasts. Crit Rev Oncol Hematol 97 (2016), 303–311.
26. [26] Carosella, ED, Ploussard, G, LeMaoult, J, Desgrandchamps, F, A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G. Eur Urol 68 (2015), 267–279.
27. [27] Carthon, BC, Wolchok, JD, Yuan, J, Kamat, A, Ng Tang, DS, Sun, J, Ku, G, Troncoso, P, Logothetis, CJ, Allison, JP, et al. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res 16 (2010), 2861–2871.
28. [28] Powles, T, Eder, JP, Fine, GD, Braiteh, FS, Loriot, Y, Cruz, C, Bellmunt, J, Burris, HA, Petrylak, DP, Teng, SL, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515 (2014), 558–562.
29. [29] Acharyya, S, Oskarsson, T, Vanharanta, S, Malladi, S, Kim, J, Morris, PG, Manova-Todorova, K, Leversha, M, Hogg, N, Seshan, VE, et al. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell 150 (2012), 165–178.
30. [30] Kalluri, R, Zeisberg, M, Fibroblasts in Cancer. Nat Rev Cancer 6 (2006), 392–401.
31. [31] Sato, H, Takino, T, Okada, Y, Cao, J, Shinagawa, A, Yamamoto, E, Seiki, M, A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 370 (1994), 61–65.
32. [32] Erler, JT, Bennewith, KL, Cox, TR, Lang, G, Bird, D, Koong, A, Le, QT, Giaccia, AJ, Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 15 (2009), 35–44.
33. [33] Osuala, KO, Sameni, M, Shah, S, Aggarwal, N, Simonait, ML, Franco, OE, Hong, Y, Hayward, SW, Behbod, F, Mattingly, RR, et al. Il-6 signaling between ductal carcinoma in situ cells and carcinoma-associated fibroblasts mediates tumor cell growth and migration. BMC Cancer, 15, 2015, 584.
34. [34] Maniecki, MB, Etzerodt, A, Ulhøi, BP, Steiniche, T, Borre, M, Dyrskjøt, L, Orntoft, TF, Moestrup, SK, Møller, HJ, Tumor-promoting macrophages induce the expression of the macrophage-specific receptor CD163 in malignant cells. Int J Cancer 131 (2012), 2320–2331.
35. [35] Konur, A, Kreutz, M, Knüchel, R, Krause, SW, Andreesen, R, Cytokine repertoire during maturation of monocytes to macrophages within spheroids of malignant and non-malignant urothelial cell lines. Int J Cancer 78 (1998), 648–653.
36. [36] Yeh, CR, Hsu, I, Song, W, Chang, H, Miyamoto, H, Xiao, GQ, Li, L, Yeh, S, Fibroblast ERα promotes bladder cancer invasion via increasing the CCL1 and IL-6 signals in the tumor microenvironment. Am J Cancer Res 5 (2015), 1146–1157.
37. [37] Ioachim, E, Michael, M, Salmas, M, Michael, MM, Stavropoulos, NE, Malamou-Mitsi, V, Hypoxia-inducible factors HIF-1alpha and HIF-2alpha expression in bladder cancer and their associations with other angiogenesis-related proteins. Urol Int 77 (2006), 255–263.
38. [38] Spivak-Kroizman, TR, Hostetter, G, Posner, R, Aziz, M, Hu, C, Demeure, MJ, Von Hoff, D, Hingorani, SR, Palculict, TB, Izzo, J, et al. Hypoxia triggers hedgehog-mediated tumor-stromal interactions in pancreatic cancer. Cancer Res 73 (2013), 3235–3247.
39. [39] Hafner, C, Knuechel, R, Zanardo, L, Dietmaier, W, Blaszyk, H, Cheville, J, Hofstaedter, F, Hartmann, A, Evidence for oligoclonality and tumor spread by intraluminal seeding in multifocal urothelial carcinomas of the upper and lower urinary tract. Oncogene 20 (2001), 4910–4915.
40. [40] Hafner, C, Knuechel, R, Stoehr, R, Hartmann, A, Clonality of multifocal urothelial carcinomas: 10 years of molecular genetic studies. Int J Cancer 101 (2002), 1–6.
41. [41] Schioppa, T, Uranchimeg, B, Saccani, A, Biswas, SK, Doni, A, Rapisarda, A, Bernasconi, S, Saccani, S, Nebuloni, M, Vago, L, et al. Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med 198 (2003), 1391–1402.
42. [42] Levental, KR, Yu, H, Kass, L, Lakins, JN, Egeblad, M, Erler, JT, Fong, SF, Csiszar, K, Giaccia, A, Weninger, W, et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 139 (2009), 891–906.